Ask the Scholar

Page 14 of 57
I can add historical knowledge about this page.

Page image

Page 14

OCR

Procedural Fairness FDA's ability to regulate tobacco products should not be subject to different or more onerous standards or procedures than are applied to "drugs" or "devices". The FDA should be empowered to "consider" all factors the Secretary deems relevant to the rule's or standard's overall impact on the public health, including but not limited to technological feasibility, the likely response of consumers to the proposal, and the likelihood that the change will result in the creation of a substantial black market. But the Secretary should not have the burden of making a formal determination with regard to any of these factors. Procedurally, the Secretary should be entitled to establish "product performance standards" through the use of "notice and comment rulemaking." Tobacco product performance standards should be subject to the same level of Congressional and judicial review as is applied to other products, but no greater. It shall not be a requirement that a tobacco product performance standard, including a standard that requires the elimination of a harmful component of a tobacco product, including nicotine, can take effect only upon an affirmative vote of Congress. Authority Over Youth Access and Tobacco Advertising and Marketing FDA should be the federal agency with primary rulemaking and enforcement authority over restrictions on a) youth access to tobacco products, b) tobacco advertising and marketing that appeals to children. Health Information Disclosure FDA should be entitled to receive from the tobacco industry all documents and information in the tobacco industry's possession relevant to the health effects of tobacco products, nicotine and its effect on the body, addiction, marketing to children and the effect of marketing on children, and such other information that the Secretary deems necessary to permit the FDA to protect the public health. FDA should have the authority to subpoena this information when necessary. None of this information should be withheld from the FDA on the ground that it is confidential, represents a trade secret, or is subject to a claim of lawyer client privilege. Respecting legitimate trade secrets and legitimate claims of lawyer client privilege, the FDA should have the authority to make information and documents available to the public as the FDA deems to be in the public's interest. The authority to develop accurate measures and test for tar, nicotine, carbon monoxide yields, as well as other components of tobacco products and tobacco smoke, should be transferred from the FTC to the FDA. Ingredients FDA should have the authority to require the tobacco industry to provide it with a complete list of all tobacco ingredients and additives, by brand and by quantity, and should be entitled to require that this information be disclosed to the public in a manner that does not disclose legitimate trade secrets. It should be illegal for any tobacco manufacturer to use any ingredient or additive that is harmful or which contributes to the harm of the product or which boosts the impact of nicotine. The burden should be on the tobacco manufacturer to demonstrate to the FDA that each ingredient and additive is safe in the quantity used under the conditions of intended use.

Page data

Page
14
Source index
0
Type
photo
Media ID
662f4ab814b0c220
Size
unknown

Document data

ID
26413531
Core
doc
Type
document
DTO data
{
    "id": "26413531",
    "sourceUrl": "https://catalog.archives.gov/id/26413531",
    "contentType": "document",
    "title": "Tobacco Effective National Action to Control Tobacco (ENACT) [2]",
    "citationUrl": "https://catalog.archives.gov/id/26413531",
    "collections": [
        "Records of the Domestic Policy Council (Clinton Administration)",
        "Bruce Reed's Tobacco Files"
    ],
    "iiifBase": "https://s3.amazonaws.com/NARAprodstorage/opastorage/live/31/4135/26413531/content/presidential-libraries/clinton/foia/2011-0299-S-Tobacco/2011-0299-S-Tobacco-JPG/Box_265/42-t-7367462-20110299S-265-010-2015/42_t_7367462_20110299S_265_010_2015_Page_001.JPG",
    "thumbnailUrl": "https://s3.amazonaws.com/NARAprodstorage/opastorage/live/31/4135/26413531/content/presidential-libraries/clinton/foia/2011-0299-S-Tobacco/2011-0299-S-Tobacco-JPG/Box_265/42-t-7367462-20110299S-265-010-2015/42_t_7367462_20110299S_265_010_2015_Page_001.JPG",
    "largeImageUrl": "https://s3.amazonaws.com/NARAprodstorage/opastorage/live/31/4135/26413531/content/presidential-libraries/clinton/foia/2011-0299-S-Tobacco/2011-0299-S-Tobacco-JPG/Box_265/42-t-7367462-20110299S-265-010-2015/42_t_7367462_20110299S_265_010_2015_Page_001.JPG",
    "imageCount": 57,
    "hasImages": true,
    "source": "import",
    "hasTranscription": false
}

Context sent to Scholar

Document identity
{
    "localId": "26413531",
    "label": "Tobacco Effective National Action to Control Tobacco (ENACT) [2]",
    "core": "doc",
    "dtoType": "document",
    "citationUrl": "https://catalog.archives.gov/id/26413531"
}
Document source metadata
{
    "id": "26413531",
    "sourceUrl": "https://catalog.archives.gov/id/26413531",
    "contentType": "document",
    "title": "Tobacco Effective National Action to Control Tobacco (ENACT) [2]",
    "citationUrl": "https://catalog.archives.gov/id/26413531",
    "collections": [
        "Records of the Domestic Policy Council (Clinton Administration)",
        "Bruce Reed's Tobacco Files"
    ],
    "iiifBase": "https://s3.amazonaws.com/NARAprodstorage/opastorage/live/31/4135/26413531/content/presidential-libraries/clinton/foia/2011-0299-S-Tobacco/2011-0299-S-Tobacco-JPG/Box_265/42-t-7367462-20110299S-265-010-2015/42_t_7367462_20110299S_265_010_2015_Page_001.JPG",
    "thumbnailUrl": "https://s3.amazonaws.com/NARAprodstorage/opastorage/live/31/4135/26413531/content/presidential-libraries/clinton/foia/2011-0299-S-Tobacco/2011-0299-S-Tobacco-JPG/Box_265/42-t-7367462-20110299S-265-010-2015/42_t_7367462_20110299S_265_010_2015_Page_001.JPG",
    "largeImageUrl": "https://s3.amazonaws.com/NARAprodstorage/opastorage/live/31/4135/26413531/content/presidential-libraries/clinton/foia/2011-0299-S-Tobacco/2011-0299-S-Tobacco-JPG/Box_265/42-t-7367462-20110299S-265-010-2015/42_t_7367462_20110299S_265_010_2015_Page_001.JPG",
    "imageCount": 57,
    "hasImages": true,
    "source": "import",
    "hasTranscription": false
}
Document source extras
{
    "url": "https://catalog.archives.gov/id/26413531",
    "naId": 26413531,
    "levelOfDescription": "fileUnit",
    "otherTitles": [
        "42-t-7367462-20110299S-265-010-2015"
    ],
    "recordType": "description",
    "ocrSource": "nara-archive"
}
Page context
{
    "seq": 14,
    "pageIndex": 0,
    "type": "photo",
    "url": "https://s3.amazonaws.com/NARAprodstorage/opastorage/live/31/4135/26413531/content/presidential-libraries/clinton/foia/2011-0299-S-Tobacco/2011-0299-S-Tobacco-JPG/Box_265/42-t-7367462-20110299S-265-010-2015/42_t_7367462_20110299S_265_010_2015_Page_014.JPG",
    "mediaId": "662f4ab814b0c220",
    "ocrText": "Procedural Fairness FDA's ability to regulate tobacco products should not be subject to different\nor more onerous standards or procedures than are applied to \"drugs\" or \"devices\".\nThe FDA should be empowered to \"consider\" all factors the Secretary deems relevant to the\nrule's or standard's overall impact on the public health, including but not limited to technological\nfeasibility, the likely response of consumers to the proposal, and the likelihood that the change\nwill result in the creation of a substantial black market. But the Secretary should not have the\nburden of making a formal determination with regard to any of these factors.\nProcedurally, the Secretary should be entitled to establish \"product performance standards\"\nthrough the use of \"notice and comment rulemaking.\" Tobacco product performance standards\nshould be subject to the same level of Congressional and judicial review as is applied to other\nproducts, but no greater. It shall not be a requirement that a tobacco product performance\nstandard, including a standard that requires the elimination of a harmful component of a tobacco\nproduct, including nicotine, can take effect only upon an affirmative vote of Congress.\nAuthority Over Youth Access and Tobacco Advertising and Marketing FDA should be the\nfederal agency with primary rulemaking and enforcement authority over restrictions on a) youth\naccess to tobacco products, b) tobacco advertising and marketing that appeals to children.\nHealth Information Disclosure FDA should be entitled to receive from the tobacco industry all\ndocuments and information in the tobacco industry's possession relevant to the health effects of\ntobacco products, nicotine and its effect on the body, addiction, marketing to children and the\neffect of marketing on children, and such other information that the Secretary deems necessary to\npermit the FDA to protect the public health. FDA should have the authority to subpoena this\ninformation when necessary. None of this information should be withheld from the FDA on the\nground that it is confidential, represents a trade secret, or is subject to a claim of lawyer client\nprivilege.\nRespecting legitimate trade secrets and legitimate claims of lawyer client privilege, the FDA\nshould have the authority to make information and documents available to the public as the FDA\ndeems to be in the public's interest.\nThe authority to develop accurate measures and test for tar, nicotine, carbon monoxide yields, as\nwell as other components of tobacco products and tobacco smoke, should be transferred from the\nFTC to the FDA.\nIngredients FDA should have the authority to require the tobacco industry to provide it with a\ncomplete list of all tobacco ingredients and additives, by brand and by quantity, and should be\nentitled to require that this information be disclosed to the public in a manner that does not\ndisclose legitimate trade secrets. It should be illegal for any tobacco manufacturer to use any\ningredient or additive that is harmful or which contributes to the harm of the product or which\nboosts the impact of nicotine. The burden should be on the tobacco manufacturer to demonstrate\nto the FDA that each ingredient and additive is safe in the quantity used under the conditions of\nintended use."
}